LAG3 and neoplasm: To investigate the latter, we first performed in vitro LLC-eGFP/OVA target cell-specific killing by OT-I cells with or without the addition of Ly6C+ tumor-infiltrated monocytes, anti-PD-L1, -VISTA, -LAG-3, -SIRP-α or -TIM-3 mAbs or their combination with anti-PD-L1 (Figures 6B-D).